郑州近视800度视力是多少(郑州激光矫正视力手术价格) (今日更新中)

BEIJING, March 24 (Xinhuanet) -- A new study has found that Actos, a medicine treats onset diabetes, could also reduce the diabetes risk in people with prediabetes.The study, which was published Wednesday in New England Journal of Medicine, followed 602 prediabetics whose obesity, ethnicity, family history and other factors put them at high risk of developing diabetes.The research findings showed that Actos, generically known as pioglitazone, reduced the odds of developing Type 2 diabetes by 72 percent in people with prediabetes.Only 2.1 percent of those who took Actos developed diabetes each year over the three years of the study, compared with 7.6 percent of those who took a placebo.Lead author of the study Ralph DeFronzo said, "The 72 percent reduction is the largest decrease in the conversion rate of pre-diabetes to (Type 2) diabetes that has ever been demonstrated by any intervention, be it diet, exercise or medication."However, Actos can have significant side effects, including water retention, moderate weight gain, and increased risk of bone fractures.

MADRID, Jan. 24 (Xinhua) -- The Spanish branch of Industrial and Commerce Bank of China (ICBC) was officially inaugurated in Madrid Monday.ICBC President Jiang Jianqing, Spanish Minister of Industry, Tourism and Commerce Miguel Sebastian and Chinese Ambassador to Spain Zhu Bangzao attended an inaugural gala dinner here.In a speech, Jiang thanked the Spanish government and authorities for allowing the ICBC to open in Spain and highlighted the importance of the Spanish economy and the close relations between the two countries.Sebastian said Spain welcomes the arrival of the biggest Chinese bank, which would further improve the already good relationship between the two counties.The Madrid branch is to provide a wide range of financial services to 166,000 Chinese nationals living in Spain.ICBC has a total of 386,723 employees and 162 foreign branches throughout the World.

VIENNA, March 18 (Xinhua) -- The 26th Annual Congress of the European Association of Urology (2011 EAU congress) kicked off on Friday at the Vienna Austria Center in the Austrian capital Vienna.About 14,000 doctors, experts, scholars and representatives of pharmaceutical enterprises in the field of urology from more than 80 countries took part in the event, which will last till Tuesday.The EAU congress is Europe's largest fair in the field of urology. This is the third time for Vienna to host the event.The EAU congress aims to review technical innovation and technological progress in the field of urology and related subspecialties, discuss new theories, new technologies and new diagnostic methods of urological clinical trials, optimize the risk management of urological disease, and enhance doctors' practical knowledge and skills by educational activities.It also provides an important platform for related pharmaceutical, medical equipments and medical consumables manufacturers to present their latest products and technologies, and creates the opportunity of face-to-face communication between suppliers and consumers.The highlights of this year's EAU congress include the discussion of state-of-the-art kidney imaging and the application of ultrasound, computerized tomography (CT-scan) and magnetic resonance imaging (MRI).Participants are also expected to give a timely overview on the role of imaging, focal therapy and kidney biopsy in the management and follow-up of small renal masses, as well as the use of imaging in the management of urinary incontinence and other pelvic urinary pathologies.Congress organizers said that more than 200 presentations and seminars are scheduled during the five-day meeting, with an estimated 400 speakers unveiling their latest findings.

BEIJING, May 21 (Xinhua) -- China's State Food and Drug Administration (SFDA) issued a circular on Friday banning the use of Nimesulide, an anti-inflammatory drug, for children under the age of 12, considering potential side-effects such as liver and kidney damage.Nimesulide is a non-steroidal anti-inflammatory drug that first became available in Italy in 1985. It is now used in more than 50 countries and regions.The drug entered Chinese markets in 1997.According to the SFDA, while common adverse reactions to the drug include vomiting and stomache, domestic and overseas statistics indicate that more severe issues are related to the drug, such as blood coagulation disorders, decreased white blood cells and damage to liver and kidney.Previously, the SFDA only prevented the use of the drug among children one year old or younger.Also on Friday, the SFDA ordered the suspension of the production, sales and use of Duxil (almitrine and raubasine compound) due to its "unobvious" efficacy.According to the SFDA, clinical research found "little" evidence proving the drug effectively improves the cognitive ability for patients suffering vascular cognitive impairment.The drug was supposed to treat symptoms related to cognition and sensory nerve damage.The moves came after a two-month nationwide campaign was launched earlier this month to probe the quality of essential drugs and ensure drug safety.Official figures show that China's National Center for Adverse Drug Reaction Monitoring received 692,904 reports of adverse reactions in 2010, up 8.4 percent compared with those in 2009.Among the total, 109,991 cases involved new or severe adverse reactions, a year-on-year increase of 16.2 percent.

来源：资阳报